These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
210 related items for PubMed ID: 11807634
1. A randomized monocentric trial in febrile neutropenic patients: ceftriaxone and gentamicin vs cefepime and gentamicin. Cornely OA, Bethe U, Seifert H, Breuer K, Schütt-Gerowitt H, Salzberger B, Schrappe M, Fätkenheuer G. Ann Hematol; 2002 Jan; 81(1):37-43. PubMed ID: 11807634 [Abstract] [Full Text] [Related]
2. Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever. Cornely OA, Bethe U, Salzberger B, Franzen C, Hartmann P, Steinmetz T, Fätkenheuer G, Seifert H, Diehl V, Schrappe M. Ann Hematol; 2001 Feb; 80(2):103-8. PubMed ID: 11261319 [Abstract] [Full Text] [Related]
3. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Cherif H, Björkholm M, Engervall P, Johansson P, Ljungman P, Hast R, Kalin M. Scand J Infect Dis; 2004 Feb; 36(8):593-600. PubMed ID: 15370671 [Abstract] [Full Text] [Related]
4. [Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration]. Karthaus M, Südhoff T, Fenchel K, Egerer G, Kämpfe D, Ritter J, Franke A, Heil G, Peters G, Jürgens H. Wien Med Wochenschr; 1998 Feb; 148(21):481-7. PubMed ID: 10048176 [Abstract] [Full Text] [Related]
5. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients. Metallidis S, Kollaras P, Giannakakis T, Seitanidis B, Kordosis T, Nikolaidis J, Hatzitolios A, Nikolaidis P. Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729 [Abstract] [Full Text] [Related]
6. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. Gorschlüter M, Hahn C, Fixson A, Mey U, Ziske C, Molitor E, Horré R, Sauerbruch T, Marklein G, Schmidt-Wolf IG, Glasmacher A. Support Care Cancer; 2003 Jun; 11(6):362-70. PubMed ID: 12690546 [Abstract] [Full Text] [Related]
9. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Böhme A, Shah PM, Stille W, Hoelzer D. Eur J Med Res; 1998 Jul 20; 3(7):324-30. PubMed ID: 9682028 [Abstract] [Full Text] [Related]
18. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Kebudi R, Görgün O, Ayan I, Gürler N, Akici F, Töreci K. Med Pediatr Oncol; 2001 Apr 01; 36(4):434-41. PubMed ID: 11260566 [Abstract] [Full Text] [Related]
19. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. Tamura K. Int J Antimicrob Agents; 2005 Dec 01; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072 [Abstract] [Full Text] [Related]